Rolapitant as an Antiemetic in Malignant Glioma Patients Receiving Radiotherapy and Temozolomide
Status:
Recruiting
Trial end date:
2023-04-01
Target enrollment:
Participant gender:
Summary
The purpose of this phase 2 study is to assess the efficacy and patient satisfaction of oral
rolapitant plus ondansetron vs. oral ondansetron monotherapy in malignant glioma (MG)
patients receiving standard of care radiation (RT) and temozolomide (TMZ) therapy. This is a
randomized phase 2 trial of rolapitant plus ondansetron vs. ondansetron monotherapy for the
prevention of chemo-radiation induced nausea and vomiting in primary MG subjects receiving RT
and concomitant multi-dose TMZ.